Financial Report: Catalent

Catalent
1Q Revenues: $543.9 million (+23%)
1Q Earnings: $3.8 million (-17%)
Comments: Softgel Technologies revenue was $219.7 million in the quarter, up 18%. Growth was primarily attributable to the February 2017 Accucaps acquisition, which contributed 14 percentage points. Drug Delivery Solutions revenue was $225.8 million, up 18% primarily driven by favorable demand for certain higher margin offerings, primarily U.S. operations for oral delivery platform, and increased volume from biologics offerings, partially offset by a decrease in product participation revenue. Revenue from the Clinical Supply Services segment was $109.7 million, up 46%, due to higher volume related to storage, distribution, manufacturing, and packaging services; as well as increased lower-margin comparator sourcing activities.